Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fulcrum Therapeutics

3.46
+0.17005.17%
Pre-market: 2.82-0.6400-18.50%04:43 EDT
Volume:369.58K
Turnover:1.28M
Market Cap:186.77M
PE:-22.05
High:3.57
Open:3.25
Low:3.17
Close:3.29
Loading ...

Fulcrum Therapeutics Insider Ups Holding During Year

Simply Wall St.
·
04 Feb

Fulcrum Therapeutics Faces Genzyme Agreement Termination

TIPRANKS
·
24 Dec 2024

BRIEF-Fulcrum Therapeutics Sanofi To Terminate Collaboration And License Agreement With Fulcrum

Reuters
·
24 Dec 2024

Fulcrum Therapeutics Inc - Termination Effective April 17, 2025

THOMSON REUTERS
·
24 Dec 2024

Fulcrum Therapeutics Inc - Sanofi to Terminate Collaboration and License Agreement With Fulcrum

THOMSON REUTERS
·
24 Dec 2024

Fulcrum Therapeutics rumor highlighted in Betaville alert

TIPRANKS
·
24 Dec 2024

There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump

Simply Wall St.
·
23 Dec 2024

Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago

Simply Wall St.
·
20 Dec 2024

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why

Zacks
·
29 Nov 2024

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)

TIPRANKS
·
19 Nov 2024

Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)

Simply Wall St.
·
15 Nov 2024

Fulcrum Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Nov 2024

Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...

GuruFocus.com
·
14 Nov 2024

Fulcrum Therapeutics Inc reports results for the quarter - Earnings Summary

Reuters
·
13 Nov 2024

BRIEF-Fulcrum Therapeutics Announces Recent Business Highlights And Financial Results For Q3 2024

Reuters
·
13 Nov 2024

Fulcrum Therapeutics Q3 2024 GAAP EPS $(0.35) Beats $(0.41) Estimate, Ended The Third Quarter Of 2024 With $257.2M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into At Least 2027

Benzinga
·
13 Nov 2024

BRIEF-Fulcrum Therapeutics Q3 Basic EPS USD -0.35

Reuters
·
13 Nov 2024

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

THOMSON REUTERS
·
13 Nov 2024

Fulcrum Therapeutics Inc: Cash Runway Into at Least 2027

THOMSON REUTERS
·
13 Nov 2024

New Strong Buy Stocks for November 12th

Zacks
·
12 Nov 2024